
## **Product Data Sheet**

## **Biotin anti-human CD28**

Catalog # / Size:	2114515 / 25 μg 2114520 / 100 μg
Clone:	CD28.2
Isotype:	Mouse IgG1, κ
<b>Reactivity:</b>	Human
Preparation:	The antibody was purified by affinity chromatography, and conjugated with biotin under optimal conditions. The solution is free of unconjugated biotin.
Formulation:	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Workshop Number:	V-CD28.05
<b>Concentration:</b>	0.5



Human peripheral blood lymphocytes stained with biotinylated CD28.2, followed by Sav-PE

## **Applications:**

Applications:	Flow Cytometry
Recommended Usage:	Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is $\leq 0.5$ microg per $10^6$ cells in 100 microL volume or 100 microL whole blood. It is recommended that the reagent be titrated for optimal performance for each application.
Application Notes:	Additional reported applications (for the relevant formats) include: immunoprecipitation, immunohistochemical staining of acetone-fixed frozen tissue sections4, and <i>in vitro</i> T cell costimulation <sup>5-8</sup> . This clone was tested in- house and does not work on formalin fixed paraffin-embedded (FFPE) tissue. The CD28.2 antibody co-stimulates T cell proliferation and cytokine production in the presence of suboptimal amounts of anti-CD3 antibody. The LEAF <sup>™</sup> purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 302914). For highly sensitive assays, we recommend Ultra-LEAF <sup>™</sup> purified antibody (Cat. No. 302934) with a lower endotoxin limit than standard LEAF <sup>™</sup> purified antibodies (Endotoxin <0.01 EU/microg).
Application References:	<ol> <li>Schlossman S, <i>et al.</i> Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.</li> <li>Nunes J, <i>et al.</i> 1993. <i>Biochem. J.</i> 293:835.</li> <li>Calea-Lauri J, <i>et al.</i> 1999. <i>J. Immunol.</i> 163:62.</li> <li>Tazi A, <i>et al.</i> 1999. <i>J. Immunol.</i> 163:3511. (IHC)</li> <li>Marti F, <i>et al.</i> 2001. <i>J. Immunol.</i> 166:197. (Costim)</li> <li>Jeong SH, <i>et al.</i> 2004. <i>J. Virol.</i> 78:6995. (Costim)</li> <li>Rivollier A, <i>et al.</i> 2004. <i>Blood</i> 104:4029. (Costim)</li> <li>Scharschmidt E, <i>et al.</i> 2004. <i>Mol. Cell Biol.</i> 24:3860. (Costim)</li> <li>Scharschmidt E, <i>et al.</i> 2007. <i>Elsevier</i> 580:6819. PubMed</li> <li>Mitsuhashi M. 2007. <i>Clin Chem.</i>53:148. PubMed</li> <li>Ye Z, <i>et al.</i> 2008. <i>Infect. Immun.</i> 76:2541. PubMed</li> <li>Yoshino N, et al. 2008. <i>Stem Cells</i> 26:182. (FA) PubMed</li> <li>Yoshino N, et al. 2008. <i>J Leukoc Biol.</i> 83:853. (IP) PubMed</li> <li>Rout N, et al. 2010. <i>PLoS One</i> 5:e9787. (FC)</li> </ol>

For research use only. Not for diagnostic use. Not for resale. Sony Biotechnology Inc. will not be held responsible for patent infringement or other violations that may occur with the use of our products. Sony Biotechnology Inc. 1730 North First Street, San Jose, CA 95112 www.sonybiotechnology.com 16. Leonard JA, *et al.* 2011. *J. Virol.* 85:6867. <u>PubMed</u> 17. Nomura T, *et al.* 2012. *J. Virol.* 86:6481. <u>PubMed</u>

Description:	CD28 is a 44 kD disulfide-linked homodimeric type I glycoprotein. It is a member of the immunoglobulin superfamily and is also known as T44 or Tp44. CD28 is expressed on most T lineage cells, NK cell subsets, and plasma cells. CD28 binds both CD80 and CD86 using a highly conserved motif MYPPY in the CDR3-like loop. CD28 is considered a major co-stimulatory molecule, inducing T lymphocyte activation and IL-2 synthesis, and preventing cell death. <i>In vitro</i> studies indicate that ligation of CD28 on T cells by CD80 and CD86 on antigen presenting cells provides a costimulatory signal required for T cell activation and proliferation.
Antigen	1. Schlossman S, <i>et al.</i> Eds. 1995. Leucocyte Typing V. Oxford University Press.
References:	New York.

2. June CH, et al. 1994. Immunol. Today 15:321.

3. Linskey PS, et al. 1993. Annu. Rev. Immunol. 11:191.